Abstract:Our previous study has found this new BT technique could not only improve the target dose coverage, but also maintain the organ at risk (OARs) to a reasonable lower dose for advanced cervical cancer patients. The aim of this study is to explore potentially prognostic factors for survival and toxicity for the first time in the world. Sixty-three cervical cancer patients (FIGO stage IIB-IVA) who received ICBT+IMRT were retrospectively analyzed. They all received concomitent chemoradiotherapy. External body radiotherapy was performed with IMRT. A total dose of 45-50Gy was applied in 25 fractions for 5 weeks. The patients underwent 4 fractions BT at 6-6.5Gy/fraction twice a week. The targets and OARs were contoured by the professional physicians according to the GEC ESTRO recommendations. The complementary IMRT plan was delivered immediately after HDR-ICBT, with the applicator in position. D90, D100, V100, Vpd, V2xpd, volumes of target and D0.1cc, D1cc, D2cc, DICRU of OARs were recorded. CTCAE was used to evaluate the acute and late toxicities. The log-rank test and Cox regression mode were used for univariate and multivariate survival prognostic analyses. Logistic regression analysis was used for the toxic prognostic analyses. The 2-year local control rate (LC), distant metastasis free rate and overall survival rate were 94.8%, 84.9% and 91.6%. Both acute and late incidence of proctitis, rectal hemorrhage, small intestine obstruction and cystitis were low, the grade was not exceed G4 (Table 1.). None rectum and bladder perforation has occurred. The mean D90 of GTV, HR-CTV and IR-CTV were 93.3±4.3Gy, 81.8±2.5Gy, and 72.8±1.1Gy, and the mean D2cc of bladder, rectum, sigmoid and small intestine were lower than 75Gy. For BT dose, the mean D100 of GTV, HR-CTV and IR-CTV were 32.1±2.6, 23.2±2.2 and 14.7±1.3Gy, the mean V100 of HR-CTV and IR-CTV were 92.9%±1.2%, 92.7%±1.3%, and the mean DICRU of rectum and bladder were 22.3±4.6Gy and 18.3±3.3Gy. The D100 of IR-CTV was a prognostic factor for LC in univariate analyses among these factors (p = 0.041), but it had no statistical significance in multivariate analysis. The DICRU of bladder was a prognostic factor for the late cystitis (p = 0.045). This promising new technique could achieve the relatively higher local control rate and lower acute and late toxicity incidence. D100 of IR-CTV might be considered as a new potentially prognostic indicator for LC. DICRU of bladder still remained a prognostic factor for late cystitis, and it might have a more important role than D2cc.Scientific Abstract 2697; TableIncidence and grade of acute and late toxicityToxicityG1-2(%)G3(%)G4-5(%)Acute proctitis30.200Acute rectal hemorrhage1.600Acute small intestinal obstruction1.600Acute cystitis15.91.60Late proctitis3.200Late small intestinal obstruction1.61.60Late cystitis4.81.60Late rectal hemorrhage000 Open table in a new tab

Analysis of the survival rate with cervical cancer using 137 Cs and 192 Ir afterloading brachytherapy

Comparison of Computed Tomography- and Magnetic Resonance Imaging-Based Target Delineation for Cervical Cancer Brachytherapy

High-dose-rate brachytherapy in uterine cervix carcinoma: a comparison of dosimetry and clinical outcomes among three fractionation schedules

High Dose-Rate Afterloading In The Treatment Of Cervical-Cancer Of The Uterus

Prognostic factors for IB2-IIIB cervical cancer patients treated by radiation therapy with high-dose-rate brachytherapy in a single-institution study

Clinical efficacy of preoperative vaginal intracavitary irradiation for Stage Ib2 and IIa cervical cancer

Dinoflagellate expressed sequence tag data indicate massive transfer of chloroplast genes to the nuclear genome.

Efficacy of High-Dose-rate Brachytherapy with Different Radiation Source Activities among Cervical Cancer Patients and Risk Factors for Long-Term Outcomes: A 6-Year Retrospective Study.

Impact of radiation source activity on short- and long-term outcomes of cervical carcinoma patients treated with high-dose-rate brachytherapy: A retrospective cohort study

Californium-252 Neutron Intraluminal Brachytherapy for Treatment of 62 Cases Cervical Carcinoma

A dosimetric analysis of cervical metastases between radioactive 125I seeds implantation and external beam radiation therapy

A Clinical Observation of Cf-252 Intracavitary Radiation Combined with External-beam Irradiation in the Treatment of Esophageal Carcinoma

Prognostic Factors For Toxicity And Survival In Advanced Cervical Cancer Patients Treated With High-Dose-Rate (Hdr)-Intracavitary Brachytherapy (Icbt) Combined With Complementary Intensity Modulated Radiation Therapy (Imrt)

Radiobiological and dosimetric comparison of 60Co versus 192Ir high-dose-rate intracavitary-interstitial brachytherapy for cervical cancer

Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy Combined with Intracavitary Posterior Radiotherapy for the Treatment of Medium-Term and Advanced Cervical Cancer: Efficacy, Safety and Prognostic Factors

Efficacy ofⅠb and Ⅱ stage cervical cancer treated by intensity-modulated radiotherapy after surgery

302PChallenge in the management of bulky cervical cancer: A cross-sectional analysis

Is there a role for an external beam boost in cervical cancer radiotherapy?†

Long-term evaluation of hemofiltration at home.

Image-guided interstitial brachytherapy for recurrent cervical cancer after radiotherapy: A single institution experience

Californium-252 neutron brachytherapy combined with external pelvic radiotherapy plus concurrent chemotherapy for cervical cancer: a retrospective clinical study